

Review

Drivers and Distribution of Henipavirus-Induced Syncytia: What Do We Know?

Amandine Gamble^{1,*}, Yao Yu Yeo^{2,†}, Aubrey A. Butler^{1,†}, Hubert Tang¹, Celine E. Snedden¹, Christian T. Mason³, David W. Buchholz², John Bingham⁴, Hector C. Aguilar², and James O. Lloyd-Smith¹

¹ Department of Ecology & Evolutionary Biology, University of California Los Angeles, California, USA

² Department of Microbiology & Immunology, Cornell University, Ithaca, New York, USA

³ Department of Computational Medicine, University of California Los Angeles, California, USA

⁴ CSIRO Australian Centre for Disease Preparedness, Geelong, Victoria, Australia

* Correspondence: amandine.gamble@gmail.com

† These authors contributed equally to this work.

Submitted: 30 June 2021

Abstract: Syncytium formation, i.e., cell-cell fusion resulting in the formation of multinucleated cells, is a hallmark of infection by paramyxoviruses and other important viruses. This natural mechanism has historically been a diagnostic marker for paramyxovirus infection *in vivo* and is now widely studied for virus-induced membrane fusion *in vitro*. However, the role of syncytium formation in within-host dissemination and pathogenicity of viruses remains poorly understood. The diversity of henipaviruses and their wide host range and tissue tropism make them particularly appropriate models to characterize the drivers of syncytium formation and its implications for virus fitness and pathogenicity. Based on the henipavirus literature, we summarized current knowledge on the mechanisms driving syncytium formation, mostly acquired from *in vitro* studies, and on the *in vivo* distribution of syncytia. While these data suggest that syncytium formation widely occurs across henipaviruses, hosts and tissues, we identified important data gaps that undermined our understanding of the role of syncytium formation in virus pathogenesis. Based on these observations, we propose solutions of varying complexity to fill these data gaps, from better practices in data archiving and publication for *in vivo* studies, to experimental approaches *in vitro*.

Keywords: cell-cell fusion; henipavirus; pathogenesis; paramyxovirus; syncytium; within-host dynamics

1. Introduction

The formation of syncytia, or multinucleated cells induced by cell-cell fusion (Figure 1a), is characteristic of many viral families, including emerging and endemic *Herpesviridae* [1,2], *Retroviridae* [3,4], *Coronaviridae* [5–7], and *Paramyxoviridae* [8,9] among others. While syncytium formation is associated with many animal viruses, it remains unclear to what extent syncytia contribute to infection pathogenesis *in vivo* (i.e., disease development, including viral spread within a host and associated pathogenicity) [3,4,10]. This question is of particular interest today due to the diversity of emerging viruses that present cell-cell fusion as a distinguishing feature *in vitro*.

Syncytium formation is one of several mechanisms allowing direct cell-to-cell transmission of viral material without requiring the assembly and budding of free virions [11]. Other mechanisms of direct cell-to-cell transmission used by viruses include pore formation across tight junctions, neuronal and immunological synapses or viral-induced filopodia [11,12]. Understanding the relationship between direct cell-to-cell transmission and pathogenesis can yield significant insights on the dynamics of viral infections. For instance, direct cell-to-cell transmission may significantly contribute to virus population growth, as observed *in vitro* for human immunodeficiency virus [13]. Cell-to-cell transmission may also be associated to specific clinical manifestations of infections. For instance, in measles (MeV) infections,

persistent brain infections leading to fatal subacute sclerosing panencephalitis have been attributed to synaptic transmission [14]. Similarly, in murine retrovirus infections, brain hemorrhages have been attributed to the alteration of the blood-brain barrier via the virus-induced fusion of endothelial cells [15,16]. Hence, while free virions are crucial for viral transmission between organisms and viral spread within hosts, direct cell-to-cell transmissions may contribute greatly to pathogenesis. Yet, there remains a lack of empirical knowledge on the contribution of direct cell-to-cell transmission on viral propagation and disease development. Understanding the contribution of syncytium formation to pathogenesis would also inform on whether *in vitro* cell-cell fusion assays, which are widely used to functionally describe viruses [17–21], are useful predictors of *in vivo* dynamics.

The potential benefit of syncytium formation (and other direct cell-to-cell transmission mechanisms) for viruses has been attributed to efficient local transmission through the exploitation of preexisting cellular interactions such as cellular adhesion [12]. Indeed, during direct cell-to-cell transmission, the virion assembly and budding steps are skipped, potentially accelerating virion production and dissemination [11]. Direct cell-to-cell transmission may also facilitate evasion from the humoral immune response [22]. However, syncytium formation may also come with costs, such as inducing host cell apoptosis, as observed in MeV-infected immune cells [23–26], which may ultimately be detrimental to viral replication. It is thus not obvious whether syncytium formation has a positive, negative or neutral effect on virus replication and dissemination. Unfortunately, *in vitro* studies of cell-cell fusion and free-virion production have historically been conducted independently [12,27], with the former being the focus of membrane fusion mechanistic studies (e.g., [19,28–30]) and the latter used to measure viral replication (by quantifying viral material in cell culture supernatant; e.g., [31,32]). *In vivo*, there has been no attempt to systematically map the occurrence of syncytia across virus and/or host species. Consequently, the relationship between syncytium formation and pathogenesis remains poorly understood.

Among the many emerging infectious viruses exhibiting syncytium formation, the *Henipavirus* genus (belonging to the *Paramyxoviridae* family) is of particular concern due to the high fatality rates of Hendra (HeV) and Nipah (NiV) viruses in humans [33]. The recent discovery of 20 novel henipaviruses (HNVs) in wild bats and rodents — including Cedar virus (CedV), Kumasi virus (KuV), and Mojiang virus (MojV) [34–36] — and evidence of spillovers to human populations [37] have further elevated concerns regarding the diversity and the zoonotic, pathogenic and pandemic potentials of HNVs. Emerging evidence suggests that HNVs exhibit varying levels of pathogenicity in different hosts. For example, while HeV and NiV are highly pathogenic in susceptible hosts including humans [33], CedV appears non-pathogenic in animal models [31,35]. However, comparative studies involving multiple host and virus species are necessary to uncover the importance of different factors, such as syncytium formation, in HNV pathogenicity.

Although reviews of histopathological findings following HNV infections are available [31,38–42], it is difficult to compare results from different studies as it is unclear which samples were actually screened for syncytia. For instance, syncytia were reported in cats in endothelial and respiratory epithelial cells following NiV infection and only in endothelial cells following HeV infection [38], but it is not clear whether respiratory epithelial cells were even screened for syncytium formation following HeV infections. This lack of systematic reporting limits our ability to understand the of syncytium formation in infection pathogenesis, and whether this trait can be used to assess the zoonotic and pathogenic potentials of emerging viruses. In this context, the objectives of this review are (1) to summarize current knowledge regarding the mechanisms driving syncytium formation following HNV infections, mostly acquired from *in vitro* experiments, and (2) to identify patterns of syncytium distribution *in vivo* based on a meta-analysis of literature data. We highlight the observed patterns and their concordance or discordance between *in vitro* and *in vivo* studies, discuss the fundamental and practical implications, and identify future directions for the study of virus-induced syncytium formation.




Figure 1. Molecular mechanisms and cellular manifestations of henipavirus-induced syncytium formation. **a** Syncytia are multinucleated cells formed from the fusion of an infected cell with a susceptible cell. Syncytia can be observed both *in vitro* (in cell culture) and *in vivo* (here in a Guinea pig). *In vivo*, syncytia are observed in a wide range of tissues, including the vascular, respiratory, nervous, lymphatic and urinary systems, particularly (but not exclusively) at endothelial and epithelial interfaces. **b** Fusion protein maturation via the proteolytic activation by host cathepsins in endosomes. **c** Membrane fusion cascade via the interactions between viral envelope proteins (F and G) and host receptors (ephrins). Membrane fusion is a pH-independent process using an attachment-mediated triggering mechanism of the fusion protein. Steps preceding membrane fusion (in particular infection, viral replication, and viral protein expression and egress) are detailed in Howley and Knipe 2020 [43]. Visual created using [BioRender.com](https://www.biorender.com).

2. Insights on syncytium formation from *in vitro* studies

2.1. The molecular prerequisites of syncytium formation

HNV-induced membrane fusion, either at the virus-cell or cell-cell interface, is driven by the interactions between the viral attachment glycoprotein (G), the fusion glycoprotein (F, a class I fusion protein) and the host receptors — notably membrane proteins of the ephrin family (Figure 1c). Studies into the cascade of interactions between F, G and ephrin receptors are dominated by *in vitro* experiments using cells transfected with wild-type or mutant F and G and measuring cell-cell fusion as an output (Box 1; Figure 2) [19,28–30,44]. Briefly, the binding of G to a compatible ephrin first induces conformational changes in G that expose a sequestered F-triggering region on its stalk domain, which then triggers the unfolding of F [28,29,45]. The fusion peptide of F anchors onto the target cell membrane and adopts a pre-hairpin intermediate conformation. This is followed by the

coalescence of F that generates a six-helix bundle conformation, a process that induces hemifusion, pore formation (membrane fusion), and pore expansion [44,46]. The molecular mechanisms driving the transition from hemifusion to fusion pore formation and expansion remain poorly understood, despite the critical importance of these steps for completing syncytium formation.




Figure 2. Henipavirus-induced syncytia *in vitro*. **a-b** HEK293T cells transfected with the F and G proteins of NiV (a) and CeV (b) *in vitro*. White arrowheads point towards syncytia (a: one large syncytium encompassing more than 100 nuclei; b: two syncytia encompassing approximately 20-30 nuclei each). Detailed methods are available in Yeo et al. 2021 [45].

Membrane fusion is thus highly dependent on host receptor expression. HNVs bind different ephrins with high specificities. HeV and NiV bind ephrin B2 and B3 [17,18,47,48] (although NiV has a higher affinity for ephrin B3 than HeV [48]), CeV binds ephrin A2, A5, B1, B2, and mouse A1 [49,50], and KuV binds ephrin B2 [51]. While receptor usage differences across host species is presumably minimal because ephrins are highly conserved [52,53], a notable exception is the ability of CeV to bind mouse but not human ephrin A1 due to a single amino-acid difference [49], which highlights the specificity of HNV receptor recognition. The receptor(s) for MojV remain elusive, though ephrin B2 and B3, sialic acid, and CD150 – corresponding to the three receptor families currently known to be used by paramyxoviruses – have been ruled out [54].

Prior to membrane fusion, the proteolytic cleavage of immature F proteins (F_0) into mature subunits (F_{1-2}) is necessary (Figure 1b) to expose the concealed fusion peptide in the F_1 region. F_0 is cleaved by the cathepsin family proteases found in host cell endosomes. Cathepsin usage differs between cell lines (e.g. cathepsin B in canine kidney MDCK cells [55], cathepsin L in monkey kidney Vero cells [56,57]). Cleavage occurs as F_0 undergoes endocytic recycling [46], a constitutive process, thus enabling constant presentation of mature F_{1-2} at the surface of infected cells. HNV-induced membrane fusion is thus a pH-independent process, allowing membrane fusion to occur at the cell surface in physiologic conditions, a prerequisite to cell-cell fusion.

Beyond the need for host ephrin receptors and cathepsin proteases, recent studies suggest that HNV-induced membrane fusion is modulated by several other factors ranging from membrane composition to intrinsic properties of F and G. For instance, membrane cholesterol levels correlate with the intensity of cell-cell fusion induced by NiV glycoproteins [30]. The study of HNV mutants also revealed that the early and late steps of the membrane fusion cascade are modulated by several regions of G head and stalk domains [28,29,45] and of F [58,59]. Finally, N- and O-glycans in most paramyxoviral glycoproteins have been shown to modulate protein expression, folding and transport; for HNVs in particular, several N- and O-glycans in NiV and HeV G and F modulate virus-cell and cell-cell fusion independently of protein expression [60–62]. It is worth noting that, although membrane fusion levels induced by NiV and HeV are similar [21], some N- and O- glycans of NiV and HeV G and F modulate syncytium formation differently [63–65]. In addition, while cell-cell fusion and virus-cell fusion mechanisms are presumably driven by similar underlying mechanisms, incongruities have been reported. For instance, depleting NiV matrix protein reduced viral-cell fusion whilst

enhancing cell-cell fusion [66]. In coronaviruses, cleavage of the spike protein (which supports both attachment and fusion) enhances cell-cell fusion, but not virus-cell fusion [6]. Collectively, these studies demonstrate the complexity of the membrane fusion process and highlight the need for comparative studies considering both virus-cell and cell-cell fusion.

Box 1. Methodological considerations of the study of syncytium formation *in vitro* and *in vivo*.

Inducing cell-cell fusion *in vitro*. Syncytia can be observed in cell cultures infected with live viruses. Another approach to obtain syncytia *in vitro*, referred to as the “fusion assay”, consists in transfecting non-infected cells with plasmids encoding viral glycoproteins (called “effector” cells), and to put them in contact with susceptible cells (“target” cells; Figure 2) [17]. Cell-cell fusion can occur between effector and target cells obtained from different cell lines (e.g., [17]).

Opportunities from controlled *in vitro* conditions. Selectively transfecting genes into cells allows a high degree of control and eliminates other processes that may influence cell-cell fusion such as viral replication and budding. In contrast, live virus infection into cell culture requires successful infection and completion of a full replicative cycle, which ultimately affect cell-cell fusion via their impact on viral protein expression. More generally, *in vitro* studies enable a high degree of experimental flexibility to elucidate minute details relevant to cell-cell fusion that are not attainable in *in vivo* systems, either by controlling or including the quantification of specific variables. Examples include the ability to artificially engraft glycoproteins with reporter tags to monitor intracellular trafficking [67] and assess cell-surface expression [17], or the ability to explore the effect of specific mutations on membrane fusion [62], among others.

Biological constraints specific to *in vivo* conditions. Additional factors are at play *in vivo*. First, tissue localization and connectivity can greatly impact the infection probability of specific tissues, and ultimately determine syncytia formation independently of cell susceptibility. Second, cell-cell fusion requires close and stable contact between cells [13]. While this is generally not an issue *in vitro*, it can have varying consequences *in vivo*. Cell motility may represent an obstacle to syncytium formation, while physiologic cellular interactions (e.g., between endothelial or epithelial cells [68]) may favor syncytium formation. Finally, host immunity may be a critical modulator of cell-cell fusion. For instance, neutralizing antibodies produced as part of adaptive immunity are likely to impact cell-cell fusion by binding viral glycoproteins at the surfaces of infected cells.

Detecting and quantifying syncytia *in vitro* and *in vivo*. Cell-cell fusion *in vivo* is usually observed using classical histological approaches, whereby tissue samples collected from animals are fixed, thinly-sliced, stained, and visualized under a microscope (Figure 3). Meanwhile, because cell cultures *in vitro* are monolayers, it is possible to directly visualize cell-cell fusion without fixation or staining (Figure 2). Reporter genes (e.g. β -galactosidase [69], β -lactamase [62], dual-split protein [70] assays) are increasingly commonly used to assist in the detection of cell-cell fusion, making *in vitro* assays potentially more sensitive for syncytium detection and enabling a more accurate quantification of cell-cell fusion.

2.2. Occurrence of henipavirus-induced syncytia across viruses and cell lines

In vitro studies have identified virus and host factors, such as ephrin binding of G and cathepsin cleavage of F, that may account for differences in susceptibility to syncytium formation across hosts and tissues. Syncytium formation has been observed for all five known HNVs in a wide range of cell lines including cells from the kidney, lung, brain, and vascular and lymphatic systems of primates, hamsters or swine (Table 1). The main factor driving susceptibility to cell-cell fusion *in vitro* appears to be the expression of functional receptors. For instance, HeV, NiV, CedV or KuV-induced cell-cell fusion in refractory cells can be rescued upon the introduction of a functional ephrin receptor [17,47,49–51].

Although a wide range of cell lines are susceptible to HNV-induced cell-cell fusion and qualitative patterns (susceptible *versus* refractory to cell-cell fusion) seem conserved across HNVs, quantitative variations have been reported. For instance, CedV induces significantly less cell-cell fusion than NiV in human kidney HEK293T cells [45]. Similarly, KuV and MojV also appear to form fewer syncytia than NiV in HEK293T and hamster kidney BHK cells [20,54]. However, the mechanisms underlying these quantitative variations remain unclear due to the many factors involved in cell-cell fusion, as described above.

Furthermore, for a given virus, variations in syncytium formation also exist across cell lines. For instance, NiV glycoproteins produce more fusion in Vero than HEK293T cells [17]. HeV glycoproteins produce more fusion in rabbit kidney RK13 cells than Vero cells [69]. Infections of bat kidney PaKiT03 cells and HEK293T cells with live HeV resulted in lower levels of cell-cell fusion in PaKiT03 cells, as

well as sharp differences in host gene expression profiles [71], suggesting multiple host-specific factors involved in the regulation of HNV-induced syncytium formation, and further highlighting the need for comparative studies.

Table 1. Occurrence of henipavirus-induced syncytia *in vitro*. A “+” indicates that syncytia were observed, and a “-” that syncytia were not observed, following either live infection (“live”) or viral glycoprotein transfection (“transf.”); blank cells indicate that no data are available; non-exhaustive list. There is no data from KuV and MojV live infection experiments as these viruses have not been isolated but sequenced only [36,67].

Cell line	HeV		NiV		CedV		KuV	MojV	Reference
	live	transf.	live	transf.	live	transf.	transf.	transf.	
Vero (epithelial)	+	+	+	+	+	+	-	+	[17,72,73]
HEK293T (epithelial)		+		+		+	+	+	[17,72]
A549 (epithelial)		+		+		+	+	+	[66,72]
Raji B (lymphoblast)				-					[17]
PK13 (epithelial)		-		-					[17,28]
BHK (fibroblast)	+	+	+	+	+	+	-	+	[72,73]
CHO (epithelial)		-		-		-		-	[45,47,72]
L2 (epithelial)		+				+		+	[72]
Rat2 (fibroblast)		+				+		+	[72]
EidNi (epithelial)							+		[73]
NHBE (epithelial)	+		+						[74]
SAEC (epithelial)	+		+						[74]
hOE (epithelial)	+		+						[75]
HMVEC (endothelial)				+					[17]

Vero: monkey renal epithelial cells; HEK293T: human renal epithelial cells; HEK293T: human pulmonary epithelial cells; Raji B: human lymphoblast cells; PK13: porcine renal epithelial cells; BHK: baby hamster fibroblasts; CHO: Chinese hamster ovary epithelial cells; L2: rat pulmonary epithelial cells; Rat2: rat fibroblast; EidNi: *Eidolon* bat renal epithelial cells; NHBE: human bronchi epithelial cells; SAEC: human small airway epithelial cells; hOE: human olfactory epithelial cells; HMVEC: human microvascular endothelial cells.

3. Mapping syncytium formation *in vivo*

3.1. Knowledge from other paramyxoviruses

The observation of syncytia *in vivo* following paramyxovirus infections dates back to the beginning of the 20th century, when multinucleated cells were described in lymphoid and epithelial tissues of human and non-human primate MeV cases [76,77]. The role of syncytia in MeV pathogenesis seems widely acknowledged, as syncytia are frequently mentioned in reviews on the topic [25,26]. Such reviews are largely based on old anatomical pathology studies which often report syncytia [77,78], and include very few recent studies [79]. Syncytia are also observed following Respiratory syncytial virus (RSV) infections, a virus formerly considered a paramyxovirus but recently placed in the closely related *Pneumoviridae* family [80]. RSV was named after observing syncytia induced by the virus in human cell culture [81], and syncytia were later identified as a characteristic of pulmonary lesions in RSV infections [9,82].

In vivo, the occurrence and intensity of paramyxovirus-induced syncytium formation varies among tissues, hosts and viruses. While MeV infections induce the formation of large syncytia in lymphoid and epithelial tissues, sometimes encompassing more than 30 nuclei, [25], syncytia do not seem to occur in nervous tissues [14]. MeV can nevertheless infect the brain, and neurons support MeV replication and transmission without cell-cell fusion [14]. The absence of syncytia in nervous tissues following MeV infection contrasts with canine distemper virus (CDV) infections, a closely-related paramyxovirus restricted to *Carnivora* hosts. CDV was found to induce syncytia in nervous tissues of domestic dogs (*Canis lupus familiaris*) [83]. Within nervous tissues, syncytia were more frequent in the meninges and white matter than in the grey matter, and were generally of small size (2-3 nuclei). Similarly to MeV, CDV-induced syncytia were also frequent and large in lymph nodes, often including more than 10 nuclei. However, syncytia were rare in the spleen, thymus and lungs [83]. While experimental studies of CDV have mostly been restricted to domestic dogs, syncytia following

natural infections have also been anecdotally reported across various *Carnivora* species such as foxes (*Vulpus* spp.), African wild dogs (*Lycaon pictus*), martens (*Martes* spp.) and raccoons (*Procyon* spp.) [84].




Figure 3. Henipavirus-induced syncytia *in vivo*. **a-f** Histological sections of lungs of animals experimentally infected with henipaviruses. Slides were stained with haematoxylin and eosin (a, c, e) and by immunohistochemistry for henipavirus nucleoprotein antigen (b, d, f) (brown colour). Horse lungs (a, b) show syncytia of the blood vessel endothelium (black arrowheads) and associated with the alveolar walls (white arrowhead). Ferret lungs (c, d) show syncytia of the blood vessel endothelium (black arrowheads); in these images, the endothelium has fused with attenuation and sloughing, leaving regions of the vessel wall denuded. Virus has also infected the endothelium of lymphatic vessels (white arrowheads). Ferret bronchi (e, f) show syncytia of the bronchial epithelium (black arrowheads), some of which form into stalked structures; in these images, the bronchus is filled with inflammatory and cellular debris, transferred from elsewhere in the airways.

Overall, paramyxoviruses and pneumoviruses are interesting models to investigate the clinical and diagnostic relevance of syncytium formation. However, while MeV, CDV and RSV have been relatively well studied, none represent an ideal model to study the distribution of syncytia across host and tissues due to the restriction of their host range (primates for MeV and *Carnivora* for CDV) or tissue tropism (respiratory tract for RSV). In contrast, HNVs have wide host range and tissue tropism,

in line with their zoonotic potential [52], and thus provide fertile ground to investigate the differences in syncytium formation across host species and across host tissues.

3.2. Meta-analysis of henipavirus-induced syncytium occurrence

3.2.1. Data availability

Based on a systematic review of the literature (detailed in the Supplementary Material), we built an extensive dataset compiling data on histology and viral material detection (viral genome detected by polymerase chain reaction (PCR) or viral proteins by immunohistochemistry (IHC) from 91 publications reporting data from HNV infections, corresponding to more than 1200 individuals of 18 animal species and 2 modified animal models (Figure S2). We recovered syncytium data (i.e., explicit mention of presence or absence of syncytia) from 42 publications focusing on HeV, NiV-B or NiV-M, corresponding to approximately 150 individuals from 10 species (Figure 4): African green monkey (*Chlorocebus sabaeus*), domestic pig (*Sus scrofa domesticus*), domestic dog, domestic cat (*Felis catus*), domestic ferret (*Mustela putorius furo*), Guinea pig (*Cavia porcellus*), golden hamster (*Mesocricetus auratus*), horse (*Equus ferus caballus*) and chicken (*Gallus gallus domesticus*), and humanized house mouse (*Mus musculus* with human lung xenograft). All the other studies were excluded from further analyses because they did not explicitly mention whether tissues samples were screened for syncytia or not, including only two that considered CedV [31,35]. Several studies were conducted on bats and did not report any lesions except vasculitis in grey-headed flying foxes (*Pteropus poliocephalus*) exposed to HeV [32,85,86]. Among the 44 publications reporting syncytium data, a subset of 33 publications included explicit proportions of individuals presenting syncytia, 36 publications detailed which tissue(s) were examined, and 29 publications gave information on time of sample collection relative to infection. Only 23 publications fulfilled all three of these criteria, representing data from six host species (Figures S5–S6).

When syncytia were reported, they usually were reported as presence data only (with absence data not explicitly reported), and generally did not include any quantification of syncytia (e.g., number of nuclei included in syncytia or distribution of syncytium size), limiting the potential for quantitative inference from these data (but see [42,87]). This also limits the potential for cross-comparisons to *in vitro* studies that consider both the presence and quantification of syncytia.

Data availability on syncytium occurrence is heterogeneous across viruses, hosts and tissues. Only four host species had data available for at least two viruses, enabling comparisons (Figure 4). Notably, only monkeys and hamsters had data available for all three of HeV, NiV-B and NiV-M. When syncytium data were reported, the respiratory tract (in particular the lungs) was usually included, and data were also often available from nervous and lymphatic systems. In contrast, data from the reproductive and digestive systems were rarely reported, despite some evidence of syncytia from these tissues. Within an organ system, different organs were collected across studies (e.g., different lymph nodes, different structures from the brain, etc); the resolution at which data are reported is also heterogeneous (e.g., “brain” versus specific brain structures; Figure S4). Experimental procedures also vary across studies, including eleven different virus inoculation routes, doses ranging from 68 to 5×10^8 TCID₅₀, and sample collection from 2 to 32 days post infection (Table S1 and Figures S5–S6). All of these differences across study designs present challenges for comparison and synthesis of syncytium data.

3.2.2. Syncytium distribution across tissues, hosts and viruses

Syncytia were observed in all of the 10 host species for which syncytium occurrence data are available, and affect a wide range of tissues from the respiratory, digestive, lymphatic, nervous, cardiovascular, urinary and reproductive systems (Figure 4). In particular, for almost all explored virus–host combinations, syncytia were detected in the lungs of a high proportion of individuals (60–100 %), even in the absence of gross lesions at necropsy (Figure S4). The sole exception was in

Guinea pigs infected with NiV-M, where syncytia and other lesions were rare in the lungs despite the presence of low levels of viral antigens [42]. Across all host-virus combinations, syncytia were also often detected in the spleen and, to a lesser extent, kidneys (Figure S4). Syncytia have not been reported from rabbits and rats exposed to HeV [88], nor Egyptian fruit bats exposed to NiV-B [32], but those species were only considered in one study each, and appear to not be susceptible to the virus they received.




Figure 4. Proportion of individuals presenting syncytia in different tissues following experimental henipavirus infection *in vivo*. Crossed circles indicate that no syncytia were observed; dark blue squares indicate that syncytia were observed but the exact proportion of individuals is unknown; blank spaces indicate that no data are available. Data obtained using different inoculation routes or doses and collected at different time post-infection were merged together. Available immunohistochemistry (IHC) data and the proportion of individuals presenting viral antigens are plotted in Figure S3 for comparison.

Besides the general high prevalences of syncytia in the lungs, spleen and kidneys, the data do not highlight any other clear and consistent patterns across host and virus species, potentially because of the heterogeneity in data collection and reporting. For instance, syncytia are rarely observed in nervous tissues. This disparity could represent real biological differences, or be a consequence of varying methodologies between studies. For instance, Torres-Velez et al. 2008 reports that, in guinea pigs infected with NiV-M, syncytia were present in the meninges specifically (structure composed primarily of fibroblasts and endothelial cells [89]), and it is not clear whether syncytia were also present in the neuroparenchyma and ependyma of the same individuals (Figure S4) [42]. Syncytium distribution in the brain may thus be heterogeneous, and syncytia may be missed if screening is not extensive. Most of the other studies focus on other parts of the brain, or do not report which parts of the brain were screened for syncytia, preventing comparison across studies. In addition, Guinea pigs were subjected

to different inoculation routes (Table S1) and sampling time (Figures S5–S6). It is thus not possible to infer whether this observed difference is due to the viruses, inoculation routes and/or doses, sample collection protocols, or data reporting procedures.

Comparative studies, including data obtained from different experimental conditions but following the same protocols, could help address this issue. The available data do not reveal any detectable effects of inoculation route and dose on syncytium occurrence. For instance, syncytia were detected in respiratory and lymphoid tissues, but no other tissues, of monkeys infected via intranasal exposure of 2×10^3 or 2×10^4 PFU or via aerosol exposure to approximately 1×10^3 or 1×10^4 PFU of NiV-B [90,91]. A similar pattern was reported from monkeys exposed via intratracheal exposure to 2.5×10^3 to 6.5×10^4 PFU of NiV-M [92]. Similarly, Williamson et al. 2001 reported no dose effects on syncytia formed by endothelial cells in the kidney, bladder and lungs but not in the brain of a hamster (with exposure doses of 3×10^4 and 5×10^4 TCID₅₀ of HeV, although viral inocula with different laboratory histories were used) [93]. Other studies directly comparing inoculation route or dose do not include enough data to explore potential effects on syncytium formation or occurrence [87,94–96]. Between viruses, NiV-B appears more pathogenic than NiV-M in monkeys, with infected tissues presenting more viral antigens and more lesions, including syncytia [97]. One study reported that NiV-B progression was slower than NiV-M in hamsters, but did not include any *in vivo* syncytium data [98]; another one reported no detectable difference between NiV-B and NiV-M-induced lesions of the respiratory tract of hamsters [99].

Within a given tissue, when syncytia were observed, they were often in vascular endothelial or respiratory epithelial cells (Figure 5). In particular, syncytia were observed at the epithelium of the nasal cavity and the lungs [99–102]. Syncytia were also observed, although more rarely, among epithelial cells of the tonsil [103] and the uterus [42]. More anecdotally, syncytia were reported from smooth muscle cells of blood vessels and macrophages [104]. Syncytia formed from neurons were explicitly reported only in hamsters [105] and chicken embryos [106], despite neurons being susceptible to infection in other species too [93,107].

A small number of studies present data as a function of time since infection, allowing the temporal pattern of syncytium occurrence to be examined (Figures S5–S6). Syncytia were detected as early as two days post-infection (the earliest time-point available) in several conditions. In hamsters, syncytia were detected at two days post-infection in the nasal cavity and respiratory tract following NiV-M infection, and in the respiratory tract following NiV-B infection (Figures S7–S6). In Guinea pigs infected with NiV-M, syncytia were detected at two days post-infection in the lymphatic system, but only at four days post-infection in the urinary tract (kidney and bladder) and reproductive system (ovary and uterus), and at seven days post-infection in the respiratory and gastro-intestinal tracts (Figure S6). From most of the other studies, the data do not allow the detection of temporal patterns in syncytium formation following HNV infection, because syncytia are either detected or not in a given tissue for the whole sampling period. This could be due to sampling being often restricted to a short period (up to 12 days for the majority of the studies). In particular, only three studies included data after 15 days post-infection, revealing that syncytia could still be detected in several tissues at least 28 days post-infection in Guinea pigs infected with HeV and 32 days post-infection in monkeys infected with NiV-M (Figures S5–S6). Syncytia were not detected anymore in pigs after 20 days following infection with HeV, suggesting that syncytia regressed between 7 and 20 days post-infection, but the temporal resolution of the data does not inform on the exact timing (Figure S5). However, some of the studies describe an increasing number of syncytia on the days following infection [108], and earlier appearance of syncytia in the lungs of hamsters infected with HeV compared to NiV-M [109], suggesting that data of higher resolution (notably including syncytium counts or measures of syncytium sizes, and examination of tissues across a fixed set of delays post-infection) could potentially reveal temporal dynamics in syncytium formation.




Figure 5. Map of syncytium detection across cell types and hosts following experimental henipavirus infection *in vivo*. Syncytia were considered as detected if explicitly reported at least once; blank spaces indicate that no data are available.

Two studies reported lesion scores, providing a semi-quantitative metric of the extent of syncytium formation [42,104]. Two other studies specifically scored the extent of syncytium formation, but this was done only for lung samples and concerned very small sample sizes (1 to 4 individuals per experimental condition) [87,104]. These data cannot be compared quantitatively between studies as scoring criteria may vary. However, within a study, they provide information on the heterogeneous intensity of syncytium formation and associated lesions across tissues and individuals (Figure 6). For instance, in Guinea pigs at 4 days post-infection with NiV-M, syncytium formation, together with inflammation and necrosis, were particularly intense in the spleen, moderate to intense in the lymph nodes, bladder, ovaries and uterus, and rare in the lungs, gastro-intestinal tract and kidney [42]. In contrast, Guinea pigs at 7-13 days post-infection with HeV, syncytium formation was more intense in the spleen and lungs [102]. Again, these studies should be compared with caution as, for instance, different sampling timing and notation criteria were used.

Syncytia were rarely observed in the absence of measurable viral proteins or viral genome. Though the temporal data are sparse, some host-virus pairs show evidence that viral antigens increase first, and syncytia follow (Figure 7). However, not all infected tissues exhibited syncytia (Figure 7). For instance, despite the overall low prevalence of syncytia, HNV antigens are commonly found in the nervous system of various species infected with HeV, NiV-B or NiV-M including monkeys [110], cats [94], ferrets [111,112], Guinea pigs [93] and hamsters [113]. Infected tissues generally present lesions typical of inflammation, such as the infiltration of lymphocytes and other inflammatory cells, and necrosis, haemorrhage and fibrin deposition; this is reported with or without the presence of syncytia. However, endothelial syncytia also occur independently from any other lesion, as noted in human NiV-M cases [114].




Figure 6. Scoring of histological lesions (including but not restricted to syncytia) following experimental henipavirus virus infection *in vivo*. Grey dots represent individual data points (horizontally jittered to avoid overplotting); dark blue diamonds and vertical bars represent the corresponding median and interquartile ranges; blank spaces indicate that no data are available. GI tract: gastro-intestinal tract. Individuals received different doses and were samples were collected from 2 to 17 days post infections. Lesion scores were based on observations of hematoxylin-and-eosin stained slides, and attributed as following. Hooper et al. 1997a [104]: presence of syncytia was noted on a comparative scale from 0 to 3. Hooper et al. 1997b [102]: presence of lesions was on a comparative scale from 0 to 3; lesions were syncytial cells, particularly but not exclusively in vascular endothelium, edema, cellular infiltration, and necrosis. Torres-Velez et al. 2008 [42]: 0, no abnormal findings; 1, minimal changes consisting of focal inflammation with some necrosis and rare syncytial cells; 2, moderate changes consisting of necrosis that can be focally extensive with or without inflammation, syncytial cells are usually prominent; 3, severe inflammation, extensive necrosis, hemorrhage, and numerous syncytial cells. Escaffre et al. 2018 [87]: 0, no detectable syncytia; 1, rare (1–2 syncytia/section); 2, occasional (3–5 syncytia/section); 3, frequent (5 or more syncytia/section).




Figure 7. Proportion of individuals presenting syncytia and viral antigens detected by immunohistochemistry (IHC) over time post-infection following experimental henipavirus virus infection *in vivo*. Data from the most complete studies for each virus were selected. The complete dataset showing the temporal patterns of syncytium detection is represented (Figures S5–S6).

4. Discussion

4.1. Identified patterns

Our review highlights that syncytia are widely distributed in animals infected by pathogenic HNVs (Figure 1a). Syncytia were particularly reported in the lungs, spleen and kidney of infected animals. However, syncytium detection varies across tissues, hosts, and experimental conditions, which parallels *in-vitro* observations. These variations may be driven by methodological constraints, such as lower detection probability in tissues where syncytium formation is rare, suggesting that the intensity of syncytium formation varies between tissues as well. Without specifically designed comparative studies, inferring biological differences from data collected using different protocols requires an accurate description of the observed syncytium distribution, together with an exhaustive description of the methods.

For instance, while some studies conducted on monkeys report data at a relatively fine scale, the relatively rare reports of syncytia in the nervous system does not exclude the possibility of syncytia being present but missed instead. This is exacerbated by the fact that, across all host species, the only studies explicitly screening the meninges specifically both reported syncytia in the nervous system [42,106]. Unfortunately, no other study of monkey infections explicitly mentions whether the meninges were screened for syncytia. Neuronal syncytia were also reported in hamsters [105], but they were noted as rare, suggesting that they could easily be missed. The fact that neurons formed syncytia in chicken embryos should be interpreted with caution as the spatial and temporal dynamics of ephrin expression are still poorly described [115]; in particular, as ephrins are involved in the development of various tissues, including nervous tissues [115], one could expect particularly high expression levels in embryos. Nevertheless, considering that syncytia form in neurons *in vitro* (Table 1), that neurons are susceptible to infection *in vivo* [93,106], and that HNV infections are associated with neurological disorders in many hosts (Table 2), it would not be surprising if syncytia occur in the nervous system of various species *in vivo*. In contrast, the presence of syncytia in some tissues, notably the kidney, spleen, and reproductive system, does not appear to be associated with specific clinical signs. Blood chemistry analyses have revealed evidence of kidney damage in ferrets and monkeys infected with NiV-M [110,112], but effects may vary across species [116].

Table 2. Clinical signs resulting from experimental henipavirus infections. Blank cells indicate that no data are available.

	HeV	NiV-B	NiV-M
Monkey	Respiratory disorders [109]	Respiratory disorders [90,91,97]	Respiratory and neurological disorders [92,97,107]
Pig		No clinical signs [117]	Respiratory and neurological disorders [118–121]
Dog	Mild non-specific symptoms [103]		
Cat	Respiratory disorders [88]		Respiratory disorders, no neurological disorders [94,122]
Ferret	Neurological disorders [123]	Respiratory and neurological disorder [124,125]	Respiratory and neurological disorders [124,125]
Guinea pig	Little to no respiratory disorder, neurological disorders [93,126]		Respiratory and neurological disorders [42,127]
Hamster	Respiratory and neurological disorders [108,113,128,129]	Respiratory and neurological disorders [98,129]	Respiratory and neurological disorders [87,98,101,116,128–135]
Mouse	Neurological disorders [136]	No clinical sign [137]	No clinical sign [130,137]
Horse	Respiratory disorders [138] (neurological disorders also noted from field cases [139])		
Fruit bat	No clinical sign [85,126]		No clinical sign [127]

Quantitative data from one paper suggest that the extent of syncytium formation (and other lesions) is correlated with viral antigen quantity, which is a proxy of infection intensity [42]. This pattern cannot be extrapolated beyond this study, as no others explicitly reported both syncytium formation and infection intensity scores. In addition, within a given tissue, syncytia are generally detected concomitantly or just after viral antigens, reinforcing the potential causal link between infection and syncytium formation. Experimental approaches would be necessary to assess whether this correlation is due to a positive effect of syncytium formation on viral replication, or the other way around. For instance *in vitro*, light shaking of cell culture plates might prevent cell-cell fusion, hence disentangling the contribution of free-virion transmission *versus* direct cell-to-cell transmission to viral fitness [13]. However, some other studies reported infected tissues without any syncytia. Why some tissues present syncytia and others do not, and the implications for virus fitness, remains to be elucidated. Host and tissue differences in ephrin expression and virus affinity for specific ephrins may contribute to propensity for syncytium formation. For instance, both ephrin B2 and ephrin B3 are widely expressed in endothelial cells, and syncytia are observed in some endothelial cells of all the species considered. However, ephrin B3 is expressed in the brain stem, but ephrin B2 is not, so the lower affinity of HeV, compared to NiV, for ephrin B3 could explain why syncytia were more often detected in the brain of Guinea pigs infected with NiV-M than HeV, although viral antigens and other lesions were detected in both cases [42,93]. Very little data is available on cathepsin expression across hosts, tissues and cell types [115], limiting the exploration of a potential effect of cathepsin expression on syncytium formation.

Data on syncytium occurrence following natural infection are scarce. Observations from pigs affected by the 1998 Malaysian NiV outbreak align with laboratory observations: infection resulted in respiratory and neurological syndromes, and syncytia were detected in the respiratory epithelial cells, as well as in endothelial and smooth muscle cells of the cardiovascular and lymphatic systems [140]. Similarly, horses affected by the 1994 HeV Australian HeV outbreak presented respiratory disorders and endothelial syncytia in the lungs [141]. Thus it is clear that syncytium formation *in vivo* is not limited to experimental infections, which are sometimes suspected to diverge from natural infections notably because of the high inoculation doses. In humans, HeV and NiV infections cause

acute respiratory and neurological disorders, as in non-human primate models. Syncytia have been detected in human brain, kidney and lymphoid samples, and were particularly present in blood vessels, following NiV infection [114], which aligns with observations from monkeys and other animal models. In contrast, HeV infections in humans were not associated with syncytia in the four cases for which samples were available [142]. In addition, HeV and NiV can cause late-onset or relapsed encephalitis in humans [114]. This aspect of HNV infections is difficult to study in animal models, although it would be interesting to assess whether direct cell-to-cell transmission could contribute to chronic brain infections as it does for MeV [14].

4.2. Methodological challenges of syncytium mapping

Meta-analyses can make important contributions to science by addressing questions that cannot be addressed with studies focusing on specific experimental conditions (in particular a specific host or virus species, or inoculation protocol) [143], or by increasing statistical power via increased sample sizes [144]. However, meta-analyses rely on standardized methods and detailed reports of data. Despite repeated calls for systematic data sharing over the last few decades [145], methods and data are rarely reported with enough detail to allow their comparison or integration.

For example, our meta-analysis was challenged by the lack of systematic reporting of syncytium screening and detection, despite a large majority of *in vivo* studies that included histological investigations. In particular, reported syncytium data are often limited to a brief verbal statement (e.g. “in this organ, lesions included syncytia”) or a picture of an illustrative histology slide. Similarly, quantitative data, such as viral loads, are often provided only in plots. This data is difficult to use for meta-analyses or novel statistical analyses as (1) data are often incomplete (i.e., not available for all the samples), (2) individual data from different analyses (e.g., viral load quantification and histology) cannot be combined, and (3) data extraction can be inaccurate (especially when only aggregated values, such as mean values or intervals, are reported).

Furthermore, ethical arguments highlight the importance of sharing data from studies involving animals [143]. To be usable, data should be shared in a raw format (i.e., individual data points instead of aggregated values) and accompanied by detailed metadata (e.g., individual identification, experimental treatment, etc) [146]. A culture of consistent archiving of raw data, when available, alongside published studies, as is now standard in other scientific fields, would advance the study of virology and ensure maximum scientific gain from animal experiments.

In addition to data sharing, improved practices in data collection could enable further advances in histological investigations. Several arguments suggest that syncytia could be missed even when present. First, in a given organ, syncytium distribution can be heterogeneous, notably in complex tissues composed of numerous different structures (e.g., the brain). If syncytium screening is not exhaustive (i.e., not including all the different structures), then syncytium absence cannot be inferred from syncytium non-detection (i.e. absence of evidence is not evidence of absence). In such cases, structures screened for syncytium should be precisely described (e.g., which section of the brain, and how many slices of what dimensions). Second, the few studies including syncytium intensity scores reported that intensity could vary among tissues or individuals (Figure 6), and that syncytia could be present but rare in some samples. This implies that accurate syncytium detection requires extensive screening, i.e., complete, or repeated (screening X fields from Y slides) randomized spatial coverage. Statistical approaches that capitalize on such repeated sampling are widely used in species distribution modelling, and have already been shown to be beneficial when applied to histological investigations [147]. As random screening can be time consuming and inefficient, especially in tissues showing rare syncytia and for which a high number of fields and slides would have to be screened to reach reasonable levels of confidence in detection/non-detection data [148], another option could be to use two-step designs, similar the approaches used to detected rare species [149]. In the case of syncytium detection, the first step could consist in an extensive screening of samples for viral antigens (e.g., using IHC), and the second step would focus on syncytium detection within the infection foci previously

identified. In addition to improving detection, such approaches also inform detection probability (by allowing the estimate of uncertainty in linked detection, e.g., if syncytia were not detected from a sample, what was the probability of syncytia being truly absent from this sample?) and can be used to improve process intensity estimation [150].

4.3. Comparison of syncytium occurrence patterns *in vitro* and *in vivo*

Even though cell-cell fusion *in vitro* and *in vivo* are likely governed by the same underlying mechanisms, the additional factors at play *in vivo* and the different methods used to monitor cell-cell fusion *in vitro* and *in vivo* (Box 1) raise concerns about correlations between *in vivo* and *in vitro* data. Cell lines used in *in vitro* studies, while convenient and reproducible, are not necessarily representative of the natural pathogenic effects of HNV infections. For instance, NiV and HeV infections are characterized by severe encephalitis and pneumonia (Table 2), but *in vitro* studies seldom focus on neuronal or respiratory cells but instead on kidney (e.g. Vero, HEK293T, BHK) cells. Our meta-analysis however highlighted that syncytia are often formed in kidneys *in vivo*, and in endothelial cells in general. The absence of renal syndromes may thus be due to the fact that renal functions are particularly robust rather than a consequence of tissue tropism. The correlation between *in vitro* and *in vivo* data is nevertheless imperfect. For instance, NiV and HeV can infect pigs [100,151] but show no fusion in pig kidney (PK13) cells, which likely express low to null levels of ephrin [17]. Reciprocally, while CedV is non-pathogenic *in vivo*, it induces cell-cell fusion in Vero cells [35]. This specific discordance could be explained by the fact that Vero cells lack interferons [152], while the low pathogenicity of CedV *in vivo* has been attributed to its inability to block host interferon response (because it lacks the non-structural proteins V and W) [31,35]. Hence, interferons likely impact viral replication, but not directly cell-cell fusion itself.

The over-representation of syncytia formed from epithelial and endothelial cells, compared to other cell types, may be due to either particularly high exposure of those cells to virions (due to their localisation alongside the routes of transit of viruses: in airways, vessels and ducts), or a particularly high propensity of these cells to fuse (notably because of tight intercellular junctions). In contrast, interstitial cells might be less exposed to virions and/or less likely to form syncytia even if susceptible to infection, notably as many express ephrins, as is the case for fibroblasts (e.g., Vero cells; Table 1) and neuroglial cells (e.g., astrocytes and oligodendrocytes [114]). In the case of neurons, syncytia may be rarely reported *in vivo* despite frequent observations *in vitro* because of the inherent structure of nervous tissues, where cells are connected only at their synapses, which comprise a relatively low proportion of their membranes. In both cases, syncytium formation in mono-layer cell cultures *in vitro* might be facilitated by increased contact surfaces between cells compared to *in vivo*. In addition, epithelial and endothelial syncytia may be reported more often because these cells can easily be identified based on their location, relative to other cell types, leading to a reporting bias not necessarily representative of an actual biological pattern. Interestingly, cell-cell fusion can occur between cells of different types *in vitro* (e.g., HEK293T and Vero cells [REF]). This has not been reported *in vivo*, potentially as a consequence of difficult cell identification, especially after cell-cell fusion. While *in vitro* cell type is chosen by the experimenter, cell-specific markers (e.g., by immunolabeling) could be used as part of histological analyses of samples collected *in vivo* to improve the identification of cells types involved in syncytium formation.

These examples illustrate that inferring the implications of syncytium formation for viral spread *in vivo* from *in vitro* studies should be done with caution, especially when using immortalized cell lines that present phenotypic variations from primary cell lines [153], or using mono-layer cell cultures. Nevertheless, immortalized cell lines remain as excellent practical models to investigate the implication of various factors in membrane fusion in a controlled environment.

4.4. Knowns and unknowns of syncytium formation and future directions

The wide occurrence of syncytia following HNV infections *in vivo* supports the idea that this phenotype is not a cell culture artifact, but rather a biologically relevant feature of HNVs. This observation reinforces the idea that cell-cell fusion might represent, or be associated with, a process representing, an evolutionary benefit, although experimental evidence is lacking, and we cannot exclude that syncytium formation is a by-product of other viral functions (e.g., virus-cell fusion). Beyond HNVs, the potential benefit of cell-cell fusion for viruses is also supported by the evolution of non-structural proteins in non-enveloped viruses inducing cell-cell, but not virus-cell, fusion [154]. The potential evolutionary benefit of syncytium formation could arise from enhanced ability to infect other cells, immune evasion, or the creation of multinucleated “virus factories” [10,11,22,155]. Experimental studies are needed to discriminate between these hypotheses. Paradoxically, cytopathic effects linked to syncytium formation might impair cell functioning, hence also decreasing virus replication [23,24,156,157]. In addition, cell-cell fusion might compete with virion release (e.g., if cell-cell fusion “consumes” viral glycoproteins), which is ultimately required for transmission between individuals [66]. *In vitro* studies can approximate the relative viral fitness of syncytia compared to mononucleated cells by considering the number of infectious virions released and/or secondary cellular infections caused. A more refined investigation of the correlation between syncytium size (i.e., number of cell nuclei) and viral fitness would be especially informative as this relationship might be non-monotonic (i.e., peaked) if there exists an optimal syncytium size for virion production. We thus encourage researchers studying HNVs to report detailed records of syncytium size distribution in addition to measures of virus-like particle budding (when using non-replicative artificial constructs), infectious virion release (when using live viruses *in vitro*), or viral load (when using live viruses *in vivo*).

A refined temporal and spatial description of syncytium occurrence *in vivo* could help to decipher the role of cell-cell fusion in virus dissemination and organ colonization. For instance, much interest has focused on brain colonization by HNVs and its possible relation to development of encephalitis, but the contribution of cell-cell fusion to encephalitis remains elusive. In hamsters and pigs infected with NiV-M, spatiotemporal patterns of lesions and detection of viral antigens lend support to colonization of the neurological system via axonal transport along cranial nerves, in particular the olfactory nerve [101,118]. Syncytia were observed on the epithelium of the nasal cavity, but their occurrence is not reported with a fine enough resolution to assess whether they could also play a role in virus dissemination in parallel to axonal pathways (e.g., by mapping the spatio-temporal progression of infection, as is [101], in parallel to syncytia). Disruption of the blood-brain barrier has also been suggested as an important pathway to brain colonisation by HeV and NiV [118,158]. As syncytia frequently form from endothelial cells across many organs, it is plausible that they contribute to the disruption of the blood-brain barrier. *In vitro*, the loss of impermeability of an endothelial cell culture correlated not with the beginning of viral replication, but with the appearance of syncytia and cytopathic effects [159]. Unfortunately, very few *in vivo* studies report syncytium data from brain samples.

In addition to correlative studies, experimental approaches can investigate the impact of various viral and cellular factors on syncytium formation. The identification of viral mutants supporting higher or lower levels of cell-cell fusion but conserved levels of virus-cell fusion (or vice-versa) would shed light on the viral factors driving cell-cell fusion specifically. More emphasis on quantitative measurements would also provide valuable information. For instance, measuring the impact of increased ephrin expression (using transfected cells [17]) or cathepsin activity (using enzymatic inhibitors [55–57]) on cell-cell fusion and virus-cell fusion could highlight unsuspected differences in the cellular requirements for both processes. Similarly measuring the impact of F, G and ephrin expression ratios on the two processes could bring information on the stoichiometry of the protein interactions. In particular, it remains unknown whether cell-cell fusion requires the involvement of more fusion complexes (i.e., F, G and ephrin polymers) than virus-cell fusion does. Such experimental

knowledge would be especially useful if complemented by studies on the natural expression levels of host and virus proteins using methods such as proteomics [71] or flow-virometry [160].

If syncytium formation impacts viral replication, then variations in susceptibility to syncytium formation across hosts and tissues may result in differences in viral fitness. Within a host, this can manifest as gradients of local fitness across tissues, with some permitting more viral replication than others. However, the tissues contributing to viral transmission between tissues and to replication may be different. Further, the fitness impact of syncytium formation and, more practically, the dominant mode of viral transmission may vary across tissues. Syncytia and other cell-to-cell transmission mechanisms may enable the virus to access otherwise inaccessible tissues. For instance, direct cell-to-cell transmission modes may be especially advantageous at respiratory epithelial interfaces, where mucosal immunity creates an additional barrier to infection by extracellular viruses [11]. The dissemination of HNVs by binding, but not infecting, highly mobile leukocytes is an extreme example of viral replication and within-host dissemination independence [161].

Our review highlights that susceptibility to syncytium formation generally, but not always, correlates qualitatively *in vitro* and *in vivo*. The occasional exceptions are not surprising considering the inherent complexity of *in vivo* systems (Box 1). It is critical to identify the factors modulating susceptibility to syncytium formation in order to design *in vitro* assays that can predict pathogenesis (e.g., does consideration of immune factors allow the reconciliation of *in vitro* and *in vivo* patterns?). In addition, as syncytium-forming viruses have been proposed as a strategy for cancer treatments [162], better understanding of the drivers and consequences of syncytium formation can assist the development of oncolytic virotherapy. Organoids and organs-on-chips present another promising avenue for investigation, as they occupy the middle ground between cell culture and *in vivo* experiments [163,164]. These setups notably allow researchers to recover features classically associated with *in vivo* settings, such as complex three-dimensional spatial structures involving heterogeneous cell types. They also enable ethical investigations with levels of detail classically associated to *in vitro* settings such as higher time resolutions, higher numbers of specimens, and more experimental conditions. In particular, high temporal resolution permits tracking the dynamics of syncytium and virus dissemination in space and time. Organoids have recently been used to study RSV pathogenesis in airways, and successfully recovered various features of *in vivo* infection, including syncytium formation and the recruitment of neutrophils when co-cultured with the organoids [165].

5. Conclusions

HNV-induced syncytium formation occurs widely across hosts, tissues and virus species, both *in vitro* and *in vivo*. However, susceptibility to syncytium formation varies independently from susceptibility to infection. The host and virus factors driving these variations and their impact on viral fitness and pathogenicity remain largely unknown. Considering cell-cell fusion and free-virion release together in an integrated and quantitative framework could yield considerable progress in studying the pathogenesis of HNVs and other syncytium-forming viruses. Such insights would enrich our understanding of the drivers of viral fitness more broadly. From the perspective of monitoring emerging infectious diseases, if syncytium formation can be used as a proxy of viral fitness or pathogenicity in some conditions, then cell-cell fusion assays — which can be conducted in BSL2 using only binding and fusion protein sequences — could enable rapid and ethical zoonotic risk assessment of novel paramyxoviruses. The wider use of such assays, in appropriate conditions, would contribute to a framework oriented towards the functional, rather than the genetic, characterization of emerging viruses [166].

Supplementary Materials: The following are available online at <http://www.mdpi.com//xx/xx/xx/s1>. Figure S1. Selection process of the studies included in the meta-analysis of syncytium formation following experimental henipavirus infections *in vivo*. Figure S2. Map of syncytium data availability across host and virus species following experimental henipavirus infection *in vivo*. Figure S3. Proportion of individuals presenting viral antigens detected by immunohistochemistry (IHC) following experimental henipavirus infection *in vivo*. Figure S4. Proportion of individuals presenting syncytia in different tissues following experimental henipavirus infection

in vivo. Figure S5. Proportion of individuals presenting syncytia over time post-infection following experimental Hendra virus infection *in vivo*. Figure S6. Proportion of individuals presenting syncytia over time post-infection following experimental Nipah Malaysia virus infection *in vivo*. Figure S7. Proportion of individuals presenting syncytia over time post-infection following experimental Nipah Bangladesh virus infection *in vivo*. Table S1. Studies included in the meta-analysis of syncytium formation following experimental henipavirus infections *in vivo*.

Author Contributions: Conceptualization, A.G. and J.O.L.-S.; methodology, A.G.; formal analysis, A.G. and A.A.B.; investigation, A.G., A.A.B., H.T. and Y.Y.Y.; data curation, A.A.B., H.T. and A.G.; writing—original draft preparation, A.G., Y.Y.Y.; writing—review and editing, A.G., Y.Y.Y., J.O.L.-S., J.B., H.A.C., C.E.S., A.A.B, H.T., C.T.M. and D.W.B.; visualization, A.G., J.B., Y.Y.Y., C.S. and A.A.B.; supervision, A.G., H.C.A. and J.O.L.-S; project administration, A.G. and J.O.L.-S; funding acquisition, J.O.L.-S. and H.C.A.

Funding: J.O.L.-S., A.G., H.A.C, D.W.B and Y.Y.Y. were supported by the Defense Advanced Research Projects Agency (PREEMPT D18AC00031) and the UCLA AIDS Institute and Charity Treks. J.O.L.-S. was supported by the U.S. National Science Foundation (DEB-1557022), the Strategic Environmental Research and Development Program (RC-2635) of the U.S. C.E.S was supported by the National Institutes of Health (T32 GM008185-33), as well as H.A.C, D.W.B and Y.Y.Y. (R01 AI109022 and R21 AI142377). The content of the article does not necessarily reflect the position or the policy of the U.S. government, and no official endorsement should be inferred.

Acknowledgments: We are grateful to Christopher Broder for insightful discussions. We also thank the researchers who provided additional information on the studies they conducted, in particular Sarah Jonhston, Curtis Cline, Johanna Dups, Linfa Wang, Louis Huzella, Kum Thong Wong and Mike Holbrook.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

- Heldwein, E.; Krümmenacher, C. Entry of herpesviruses into mammalian cells. *Cellular and molecular life sciences* **2008**, *65*, 1653–1668.
- Pasieka, T.J.; Maresova, L.; Shiraki, K.; Grose, C. Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. *Journal of virology* **2004**, *78*, 2884–2896.
- Symeonides, M.; Murooka, T.T.; Bellfy, L.N.; Roy, N.H.; Mempel, T.R.; Thali, M. HIV-1-induced small T cell syncytia can transfer virus particles to target cells through transient contacts. *Viruses* **2015**, *7*, 6590–6603.
- Bracq, L.; Xie, M.; Benichou, S.; Bouchet, J. Mechanisms for cell-to-cell transmission of HIV-1. *Frontiers in immunology* **2018**, *9*, 260.
- Lavi, E.; Wang, Q.; Weiss, S.R.; Gonatas, N.K. Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus. *Virology* **1996**, *221*, 325–334.
- Belouzard, S.; Millet, J.K.; Licitra, B.N.; Whittaker, G.R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses* **2012**, *4*, 1011–1033.
- Fenrich, M.; Mrdenovic, S.; Balog, M.; Tomic, S.; Zjalic, M.; Roncevic, A.; Mandic, D.; Debeljak, Z.; Heffer, M. SARS-CoV-2 dissemination through peripheral nerves explains multiple organ injury. *Frontiers in Cellular Neuroscience* **2020**, *14*, 229.
- Chang, A.; Dutch, R.E. Paramyxovirus fusion and entry: multiple paths to a common end. *Viruses* **2012**, *4*, 613–636.
- Hall, C.B. Respiratory syncytial virus. *Textbook of pediatric infectious diseases* **1992**, pp. 1633–1656.
- Compton, A.A.; Schwartz, O. They might be giants: does syncytium formation sink or spread HIV infection? *PLoS Pathogens* **2017**, *13*, e1006099.
- Cifuentes-Muñoz, N.; Dutch, R.E.; Cattaneo, R. Direct cell-to-cell transmission of respiratory viruses: The fast lanes. *PLoS pathogens* **2018**, *14*, e1007015.
- Zhong, P.; Agosto, L.M.; Munro, J.B.; Mothes, W. Cell-to-cell transmission of viruses. *Current opinion in virology* **2013**, *3*, 44–50.
- Komarova, N.L.; Anghelina, D.; Voznesensky, I.; Trinité, B.; Levy, D.N.; Wodarz, D. Relative contribution of free-virus and synaptic transmission to the spread of HIV-1 through target cell populations. *Biology letters* **2013**, *9*, 20121049.
- Lawrence, D.M.P.; Patterson, C.E.; Gales, T.L.; D’Orazio, J.L.; Vaughn, M.M.; Rall, G.F. Measles Virus Spread between Neurons Requires Cell Contact but Not CD46 Expression, Syncytium Formation, or Extracellular Virus Production. *Journal of Virology* **2000**, *74*, 1908–1918. doi:10.1128/JVI.74.4.1908-1918.2000.

15. Park, B.H.; Lavi, E.; Blank, K.J.; Gaulton, G.N. Intracerebral hemorrhages and syncytium formation induced by endothelial cell infection with a murine leukemia virus. *Journal of virology* **1993**, *67*, 6015–6024.
16. Chung, M.; Kizhatil, K.; Albritton, L.M.; Gaulton, G.N. Induction of syncytia by neuropathogenic murine leukemia viruses depends on receptor density, host cell determinants, and the intrinsic fusion potential of envelope protein. *Journal of virology* **1999**, *73*, 9377–9385.
17. Negrete, O.A.; Levroney, E.L.; Aguilar, H.C.; Bertolotti-Ciarlet, A.; Nazarian, R.; Tajyar, S.; Lee, B. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. *Nature* **2005**, *436*, 401–405.
18. Bonaparte, M.I.; Dimitrov, A.S.; Bossart, K.N.; Cramer, G.; Mungall, B.A.; Bishop, K.A.; Choudhry, V.; Dimitrov, D.S.; Wang, L.F.; Eaton, B.T.; others. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. *Proceedings of the National Academy of Sciences* **2005**, *102*, 10652–10657.
19. Aguilar, H.C.; Aspericueta, V.; Robinson, L.R.; Aanensen, K.E.; Lee, B. A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the Nipah virus membrane fusion cascade. *Journal of virology* **2010**, *84*, 8033–8041.
20. Pernet, O.; Beaty, S.; Lee, B. Functional rectification of the newly described African henipavirus fusion glycoprotein (Gh-M74a). *Journal of virology* **2014**, *88*, 5171–5176.
21. Bradel-Tretheway, B.G.; Zamora, J.L.R.; Stone, J.A.; Liu, Q.; Li, J.; Aguilar, H.C. Nipah and Hendra virus glycoproteins induce comparable homologous but distinct heterologous fusion phenotypes. *Journal of virology* **2019**, *93*.
22. Sattentau, Q. Avoiding the void: cell-to-cell spread of human viruses. *Nature Reviews. Microbiology* **2008**, *6*, 815–826. doi:10.1038/nrmicro1972.
23. Esolen, L.M.; Park, S.W.; Hardwick, J.M.; Griffin, D.E. Apoptosis as a cause of death in measles virus-infected cells. *Journal of Virology* **1995**, *69*, 3955–3958.
24. Fugier-Vivier, I.; Servet-Delprat, C.; Rivaller, P.; Rissoan, M.C.; Liu, Y.J.; Roubardin-Combe, C. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. *The Journal of experimental medicine* **1997**, *186*, 813–823.
25. Ludlow, M.; McQuaid, S.; Milner, D.; de Swart, R.L.; Duprex, W.P. Pathological Consequences of Systemic Measles Virus Infection. *The Journal of Pathology* **2015**, *235*, 253–265. doi:10.1002/path.4457.
26. Laksono, B.M.; De Vries, R.D.; McQuaid, S.; Duprex, W.P.; De Swart, R.L. Measles Virus Host Invasion and Pathogenesis. *Viruses* **2016**, *8*, 210. doi:10.3390/v8080210.
27. Kumberger, P.; Durso-Cain, K.; Uprichard, S.L.; Dahari, H.; Graw, F. Accounting for space—quantification of cell-to-cell transmission kinetics using virus dynamics models. *Viruses* **2018**, *10*, 200.
28. Liu, Q.; Stone, J.A.; Bradel-Tretheway, B.; Dabundo, J.; Montano, J.A.B.; Santos-Montanez, J.; Biering, S.B.; Nicola, A.V.; Iorio, R.M.; Lu, X.; others. Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. *PLoS Pathog* **2013**, *9*, e1003770.
29. Liu, Q.; Bradel-Tretheway, B.; Monreal, A.I.; Saludes, J.P.; Lu, X.; Nicola, A.V.; Aguilar, H.C. Nipah virus attachment glycoprotein stalk C-terminal region links receptor binding to fusion triggering. *Journal of virology* **2015**, *89*, 1838–1850.
30. Contreras, E.M.; Johnston, G.P.; Buchholz, D.W.; Ortega, V.; Monreal, I.A.; Zamora, J.L.R.; Cheung, T.; Aguilar, H.C. Roles of Cholesterol in Early and Late Steps of the Nipah Virus Membrane Fusion Cascade. *Journal of Virology* **2021**, *95*.
31. Schountz, T.; Campbell, C.; Wagner, K.; Rovnak, J.; Martellaro, C.; DeBuysscher, B.L.; Feldmann, H.; Prescott, J. Differential innate immune responses elicited by Nipah virus and Cedar virus correlate with disparate in vivo pathogenesis in hamsters. *Viruses* **2019**, *11*, 291.
32. Seifert, S.N.; Letko, M.C.; Bushmaker, T.; Laing, E.D.; Saturday, G.; Meade-White, K.; van Doremalen, N.; Broder, C.C.; Munster, V.J. Roussettus aegyptiacus bats do not support productive Nipah virus replication. *The Journal of Infectious Diseases* **2020**, *221*, S407–S413.
33. Marsh, G.A.; Wang, L.F. Hendra and Nipah viruses: why are they so deadly? *Current opinion in virology* **2012**, *2*, 242–247.
34. Drexler, J.; Corman, V.; Müller, M.; Maganga, G.; Vallo, P.; Binger, T.; others. Bats host major mammalian paramyxoviruses. *Nat Commun.* 2012; *3*: 796. *This study surveyed approximately* **2012**, *5*.
35. Marsh, G.A.; De Jong, C.; Barr, J.A.; Tachedjian, M.; Smith, C.; Middleton, D.; Yu, M.; Todd, S.; Foord, A.J.; Haring, V.; others. Cedar virus: a novel Henipavirus isolated from Australian bats. *PLoS pathogens* **2012**, *8*, e1002836.

36. Wu, Z.; Yang, L.; Yang, F.; Ren, X.; Jiang, J.; Dong, J.; Sun, L.; Zhu, Y.; Zhou, H.; Jin, Q. Novel henipa-like virus, Mojiang paramyxovirus, in rats, China, 2012. *Emerging infectious diseases* **2014**, *20*, 1064.
37. Pernet, O.; Schneider, B.S.; Beaty, S.M.; LeBreton, M.; Yun, T.E.; Park, A.; Zachariah, T.T.; Bowden, T.A.; Hitchens, P.; Ramirez, C.M.; others. Evidence for henipavirus spillover into human populations in Africa. *Nature communications* **2014**, *5*, 1–10.
38. Weingartl, H.M.; Berhane, Y.; Czub, M. Animal models of henipavirus infection: a review. *The Veterinary Journal* **2009**, *181*, 211–220.
39. Williamson, M.; Torres-Velez, F. Henipavirus: a review of laboratory animal pathology. *Veterinary pathology* **2010**, *47*, 871–880.
40. Vigant, F.; Lee, B. Hendra and Nipah infection: pathology, models and potential therapies. *Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)* **2011**, *11*, 315–336.
41. Maisner, A.; Weingartl, H.; others. Organ-and endotheliotropism of Nipah virus infections in vivo and in vitro. *Thrombosis and haemostasis* **2009**, *102*, 1014–1023.
42. Torres-Velez, F.J.; Shieh, W.J.; Rollin, P.E.; Morken, T.; Brown, C.; Ksiazek, T.G.; Zaki, S.R. Histopathologic and Immunohistochemical Characterization of Nipah Virus Infection in the Guinea Pig. *Veterinary Pathology* **2008**, *45*, 576–585. doi:10.1354/vp.45-4-576.
43. Howley, P.M.; Knipe, D.M. *Fields Virology: Emerging Viruses*; Lippincott Williams & Wilkins, 2020.
44. Aguilar, H.C.; Iorio, R.M. Henipavirus membrane fusion and viral entry. In *Henipavirus*; Springer, 2012; pp. 79–94.
45. Yeo, Y.Y.; Buchholz, D.W.; Gamble, A.; Jager, M.; Aguilar, H.C. Headless henipaviral receptor binding glycoproteins reveal fusion modulation by the head/stalk interface and post-receptor binding contributions of the head domain. *Resubmitted to Journal of Virology after minor revisions* **2021**.
46. Aguilar, H.C.; Lee, B. Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. *Expert reviews in molecular medicine* **2011**, *13*.
47. Negrete, O.A.; Wolf, M.C.; Aguilar, H.C.; Enterlein, S.; Wang, W.; Mühlberger, E.; Su, S.V.; Bertolotti-Ciarlet, A.; Flick, R.; Lee, B. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. *PLoS Pathog* **2006**, *2*, e7.
48. Negrete, O.A.; Chu, D.; Aguilar, H.C.; Lee, B. Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage. *Journal of virology* **2007**, *81*, 10804–10814.
49. Laing, E.D.; Navaratnarajah, C.K.; Da Silva, S.C.; Petzing, S.R.; Xu, Y.; Sterling, S.L.; Marsh, G.A.; Wang, L.F.; Amaya, M.; Nikolov, D.B.; others. Structural and functional analyses reveal promiscuous and species specific use of ephrin receptors by Cedar virus. *Proceedings of the National Academy of Sciences* **2019**, *116*, 20707–20715.
50. Pryce, R.; Azarm, K.; Rissanen, I.; Harlos, K.; Bowden, T.A.; Lee, B. A key region of molecular specificity orchestrates unique ephrin-B1 utilization by Cedar virus. *Life science alliance* **2020**, *3*.
51. Lee, B.; Pernet, O.; Ahmed, A.A.; Zeltina, A.; Beaty, S.M.; Bowden, T.A. Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus. *Proceedings of the National Academy of Sciences* **2015**, *112*, E2156–E2165.
52. Thibault, P.A.; Watkinson, R.E.; Moreira-Soto, A.; Drexler, J.F.; Lee, B. Zoonotic potential of emerging paramyxoviruses: Knowns and unknowns. In *Advances in virus research*; Elsevier, 2017; Vol. 98, pp. 1–55.
53. Pernet, O.; Wang, Y.E.; Lee, B. Henipavirus receptor usage and tropism. In *Henipavirus*; Springer, 2012; pp. 59–78.
54. Rissanen, I.; Ahmed, A.A.; Azarm, K.; Beaty, S.; Hong, P.; Nambulli, S.; Duprex, W.P.; Lee, B.; Bowden, T.A. Idiosyncratic Mōjiāng virus attachment glycoprotein directs a host-cell entry pathway distinct from genetically related henipaviruses. *Nature communications* **2017**, *8*, 1–11.
55. Diederich, S.; Sauerhering, L.; Weis, M.; Altmeppen, H.; Schaschke, N.; Reinheckel, T.; Erbar, S.; Maisner, A. Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment. *Journal of virology* **2012**, *86*, 3736–3745.
56. Pager, C.T.; Dutch, R.E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. *Journal of virology* **2005**, *79*, 12714–12720.
57. Pager, C.T.; Craft Jr, W.W.; Patch, J.; Dutch, R.E. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. *Virology* **2006**, *346*, 251–257.

58. Zamora, J.L.R.; Ortega, V.; Johnston, G.P.; Li, J.; André, N.M.; Monreal, I.A.; Contreras, E.M.; Whittaker, G.R.; Aguilar, H.C. Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade. *Journal of Virology* **2020**, *94*.
59. Zamora, J.L.R.; Ortega, V.; Johnston, G.P.; Li, J.; Aguilar, H.C. Novel roles of the N1 loop and N4 alpha helical region of the Nipah Virus Fusion glycoprotein in modulating early and late steps of the membrane fusion cascade. *Journal of Virology* **2021**.
60. Moll, M.; Kaufmann, A.; Maisner, A. Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein. *Journal of virology* **2004**, *78*, 7274–7278.
61. Carter, J.R.; Pager, C.T.; Fowler, S.D.; Dutch, R.E. Role of N-linked glycosylation of the Hendra virus fusion protein. *Journal of virology* **2005**, *79*, 7922–7925.
62. Aguilar, H.C.; Matreyek, K.A.; Filone, C.M.; Hashimi, S.T.; Levroney, E.L.; Negrete, O.A.; Bertolotti-Ciarlet, A.; Choi, D.Y.; McHardy, I.; Fulcher, J.A.; others. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. *Journal of virology* **2006**, *80*, 4878–4889.
63. Biering, S.B.; Huang, A.; Vu, A.T.; Robinson, L.R.; Bradel-Tretheway, B.; Choi, E.; Lee, B.; Aguilar, H.C. N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. *Journal of virology* **2012**, *86*, 11991–12002.
64. Bradel-Tretheway, B.G.; Liu, Q.; Stone, J.A.; McNally, S.; Aguilar, H.C. Novel functions of Hendra virus G N-glycans and comparisons to Nipah virus. *Journal of virology* **2015**, *89*, 7235–7247.
65. Stone, J.A.; Nicola, A.V.; Baum, L.G.; Aguilar, H.C. Multiple novel functions of henipavirus O-glycans: the first O-glycan functions identified in the paramyxovirus family. *PLoS pathogens* **2016**, *12*, e1005445.
66. Dietzel, E.; Kolesnikova, L.; Sawatsky, B.; Heiner, A.; Weis, M.; Kobinger, G.P.; Becker, S.; Von Messling, V.; Maisner, A. Nipah virus matrix protein influences fusogenicity and is essential for particle infectivity and stability. *Journal of Virology* **2016**, *90*, 2514–2522.
67. Weis, M.; Behner, L.; Hoffmann, M.; Krüger, N.; Herrler, G.; Drosten, C.; Drexler, J.F.; Dietzel, E.; Maisner, A. Characterization of African bat henipavirus GH-M74a glycoproteins. *Journal of General Virology* **2014**, *95*, 539–548.
68. Laksono, B.M.; Fortugno, P.; Nijmeijer, B.M.; de Vries, R.D.; Cordisco, S.; Kuiken, T.; Geijtenbeek, T.B.; Duprex, W.P.; Brancati, F.; de Swart, R.L. Measles skin rash: infection of lymphoid and myeloid cells in the dermis precedes viral dissemination to the epidermis. *PLoS pathogens* **2020**, *16*, e1008253.
69. Bossart, K.N.; Wang, L.F.; Eaton, B.T.; Broder, C.C. Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. *Virology* **2001**, *290*, 121–135.
70. Nakane, S.; Matsuda, Z. Dual split protein (DSP) assay to monitor cell–cell membrane fusion. In *Cell Fusion*; Springer, 2015; pp. 229–236.
71. Wynne, J.W.; Shiell, B.J.; Marsh, G.A.; Boyd, V.; Harper, J.A.; Heesom, K.; Monaghan, P.; Zhou, P.; Payne, J.; Klein, R.; others. Proteomics informed by transcriptomics reveals Hendra virus sensitizes bat cells to TRAIL-mediated apoptosis. *Genome biology* **2014**, *15*, 1–21.
72. Cheliout Da Silva, S.; Yan, L.; Dang, H.V.; Xu, K.; Epstein, J.H.; Veesler, D.; Broder, C.C. Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus. *Viruses* **2021**, *13*, 517.
73. Voigt, K.; Hoffmann, M.; Drexler, J.F.; Müller, M.A.; Drosten, C.; Herrler, G.; Krüger, N. Fusogenicity of the Ghana Virus (Henipavirus: Ghanaian bat henipavirus) Fusion Protein is Controlled by the Cytoplasmic Domain of the Attachment Glycoprotein. *Viruses* **2019**, *11*, 800.
74. Escaffre, O.; Borisevich, V.; Carmical, J.R.; Prusak, D.; Prescott, J.; Feldmann, H.; Rockx, B. Henipavirus pathogenesis in human respiratory epithelial cells. *Journal of virology* **2013**, *87*, 3284–3294.
75. Borisevich, V.; Ozdener, M.H.; Malik, B.; Rockx, B. Hendra and Nipah virus infection in cultured human olfactory epithelial cells. *Mosphere* **2017**, *2*.
76. Bunting, C. The giant-cells of measles. *The Yale journal of biology and medicine* **1950**, *22*, 513.
77. Hall, W.C.; Kovatch, R.M.; Herman, P.H.; Fox, J.G. Pathology of Measles in Rhesus Monkeys. *Veterinary Pathology* **1971**. doi:10.1177/030098587100800403.
78. Pinkerton, H.; Smiley, W.L.; Anderson, W.A.D. Giant Cell Pneumonia with Inclusions. *The American Journal of Pathology* **1945**, *21*, 1–23.
79. De Vries, R.D.; McQuaid, S.; Van Amerongen, G.; Yüksel, S.; Verburgh, R.J.; Osterhaus, A.D.; Duprex, W.P.; De Swart, R.L. Measles immune suppression: lessons from the macaque model. *PLoS Pathog* **2012**, *8*, e1002885.

80. Rima, B.; Collins, P.; Easton, A.; Fouchier, R.; Kurath, G.; Lamb, R.A.; Lee, B.; Maisner, A.; Rota, P.; Wang, L.; others. ICTV virus taxonomy profile: Pneumoviridae. *Journal of General Virology* **2017**, *98*, 2912–2913.
81. Chanock, R.; Roizman, B.; Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): isolation, properties and characterization. *American Journal of Epidemiology* **1957**, *66*, 281–290.
82. Coates, H.V.; Chanock, R.M.; others. Experimental infection with respiratory syncytial virus in several species of animals. *American journal of hygiene* **1962**, *76*, 302–12.
83. Summers, B.A.; Appel, M.J.G. Syncytia Formation: An Aid in the Diagnosis of Canine Distemper Encephalomyelitis. *Journal of Comparative Pathology* **1985**, *95*, 425–435. doi:10.1016/0021-9975(85)90047-7.
84. Beineke, A.; Baumgärtner, W.; Wohlsein, P. Cross-species transmission of canine distemper virus—an update. *One Health* **2015**, *1*, 49–59.
85. Williamson, M.; Hooper, P.; Selleck, P.; Gleeson, L.; Daniels, P.; Westbury, H.; Murray, P. Transmission studies of Hendra virus (equine morbilli-virus) in fruit bats, horses and cats. *Australian veterinary journal* **1998**, *76*, 813–818.
86. Woon, A.P.; Boyd, V.; Todd, S.; Smith, I.; Klein, R.; Woodhouse, I.B.; Riddell, S.; Crameri, G.; Bingham, J.; Wang, L.F.; others. Acute experimental infection of bats and ferrets with Hendra virus: Insights into the early host response of the reservoir host and susceptible model species. *PLoS Pathogens* **2020**, *16*, e1008412.
87. Escaffre, O.; Hill, T.; Ikegami, T.; Juelich, T.L.; Smith, J.K.; Zhang, L.; Perez, D.E.; Atkins, C.; Park, A.; Lawrence, W.S.; Sivasubramani, S.K.; Peel, J.E.; Peterson, J.W.; Lee, B.; Freiberg, A.N. Experimental Infection of Syrian Hamsters With Aerosolized Nipah Virus. *The Journal of Infectious Diseases* **2018**, *218*, 1602–1610. doi:10.1093/infdis/jiy357.
88. Westbury, H.; Hooper, P.T.; Selleck, P.; Murray, P. Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus. *Australian Veterinary Journal* **1995**, *72*, 278–279.
89. Mastorakos, P.; McGavern, D. The anatomy and immunology of vasculature in the central nervous system. *Science immunology* **2019**, *4*.
90. Geisbert, J.B.; Borisevich, V.; Prasad, A.N.; Agans, K.N.; Foster, S.L.; Deer, D.J.; Cross, R.W.; Mire, C.E.; Geisbert, T.W.; Fenton, K.A. An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys. *The Journal of Infectious Diseases* **2019**, p. jiz391. doi:10.1093/infdis/jiz391.
91. Prasad, A.N.; Agans, K.N.; Sivasubramani, S.K.; Geisbert, J.B.; Borisevich, V.; Mire, C.E.; Lawrence, W.S.; Fenton, K.A.; Geisbert, T.W. A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys. *The Journal of Infectious Diseases* **2019**, p. jiz469. doi:10.1093/infdis/jiz469.
92. Geisbert, T.W.; Daddario-DiCaprio, K.M.; Hickey, A.C.; Smith, M.A.; Chan, Y.P.; Wang, L.F.; Mattapallil, J.J.; Geisbert, J.B.; Bossart, K.N.; Broder, C.C. Development of an Acute and Highly Pathogenic Nonhuman Primate Model of Nipah Virus Infection. *PLoS ONE* **2010**, *5*, e10690. doi:10.1371/journal.pone.0010690.
93. Williamson, M.; Hooper, P.; Selleck, P.; Westbury, H.; Slocombe, R. A Guinea-Pig Model of Hendra Virus Encephalitis. *Journal of Comparative Pathology* **2001**, *124*, 273–279. doi:10.1053/jcpa.2001.0464.
94. Mungall, B.A.; Middleton, D.; Crameri, G.; Bingham, J.; Halpin, K.; Russell, G.; Green, D.; McEachern, J.; Pritchard, L.I.; Eaton, B.T.; Wang, L.F.; Bossart, K.N.; Broder, C.C. Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine. *Journal of Virology* **2006**, *80*, 12293–12302. doi:10.1128/JVI.01619-06.
95. Cong, Y.; Lentz, M.R.; Lara, A.; Alexander, I.; Bartos, C.; Bohannon, J.K.; Hammoud, D.; Huzella, L.; Jahrling, P.B.; Janosko, K.; Jett, C.; Kollins, E.; Lackemeyer, M.; Mollura, D.; Ragland, D.; Rojas, O.; Solomon, J.; Xu, Z.; Munster, V.; Holbrook, M.R. Loss in Lung Volume and Changes in the Immune Response Demonstrate Disease Progression in African Green Monkeys Infected by Small-Particle Aerosol and Intratracheal Exposure to Nipah Virus. *PLOS Neglected Tropical Diseases* **2017**, *11*, e0005532. doi:10.1371/journal.pntd.0005532.
96. Bossart, K.N.; Zhu, Z.; Middleton, D.; Klippel, J.; Crameri, G.; Bingham, J.; McEachern, J.A.; Green, D.; Hancock, T.J.; Chan, Y.P.; Hickey, A.C.; Dimitrov, D.S.; Wang, L.F.; Broder, C.C. A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection. *PLOS Pathogens* **2009**, *5*, e1000642. doi:10.1371/journal.ppat.1000642.
97. Mire, C.E.; Satterfield, B.A.; Geisbert, J.B.; Agans, K.N.; Borisevich, V.; Yan, L.; Chan, Y.P.; Cross, R.W.; Fenton, K.A.; Broder, C.C.; Geisbert, T.W. Pathogenic Differences between Nipah Virus Bangladesh

- and Malaysia Strains in Primates: Implications for Antibody Therapy. *Scientific Reports* **2016**, *6*. doi:10.1038/srep30916.
98. DeBuysscher, B.L.; de Wit, E.; Munster, V.J.; Scott, D.; Feldmann, H.; Prescott, J. Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster. *PLoS Negl Trop Dis* **2013**, *7*, e2024.
 99. Baseler, L.; de Wit, E.; Scott, D.P.; Munster, V.J.; Feldmann, H. Syrian hamsters (*Mesocricetus auratus*) oronasally inoculated with a Nipah virus isolate from Bangladesh or Malaysia develop similar respiratory tract lesions. *Veterinary pathology* **2015**, *52*, 38–45.
 100. Li, M.; Embury-Hyatt, C.; Weingartl, H.M. Experimental inoculation study indicates swine as a potential host for Hendra virus. *Veterinary research* **2010**, *41*, 33.
 101. Munster, V.J.; Prescott, J.B.; Bushmaker, T.; Long, D.; Rosenke, R.; Thomas, T.; Scott, D.; Fischer, E.R.; Feldmann, H.; De Wit, E. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. *Scientific reports* **2012**, *2*, 736.
 102. Hooper, P.; Westbury, H.; Russell, G. The lesions of experimental equine morbillivirus disease in cats and guinea pigs. *Veterinary pathology* **1997**, *34*, 323–329.
 103. Middleton, D.; Riddell, S.; Klein, R.; Arkinstall, R.; Haining, J.; Frazer, L.; Mottley, C.; Evans, R.; Johnson, D.; Pallister, J. Experimental Hendra Virus Infection of Dogs: Virus Replication, Shedding and Potential for Transmission. *Australian Veterinary Journal* **2017**, *95*, 10–18. doi:10.1111/avj.12552.
 104. Hooper, P.; Ketterer, P.; Hyatt, A.; Russell, G. Lesions of experimental equine morbillivirus pneumonia in horses. *Veterinary Pathology* **1997**, *34*, 312–322.
 105. Wong, K.; Ong, K. Pathology of acute henipavirus infection in humans and animals. *Pathology research international* **2011**, *2011*.
 106. Tanimura, N.; Imada, T.; Kashiwazaki, Y.; Sharifah, S. Distribution of viral antigens and development of lesions in chicken embryos inoculated with Nipah virus. *Journal of comparative pathology* **2006**, *135*, 74–82.
 107. Lee, J.H.; Hammoud, D.A.; Cong, Y.; Huzella, L.M.; Castro, M.A.; Solomon, J.; Laux, J.; Lackemeyer, M.; Bohannon, J.K.; Rojas, O.; others. The Use of Large-Particle Aerosol Exposure to Nipah Virus to Mimic Human Neurological Disease Manifestations in the African Green Monkey. *The Journal of infectious diseases* **2020**, *221*, S419–S430.
 108. Guillaume, V.; Wong, K.T.; Looi, R.; Georges-Courbot, M.C.; Barrot, L.; Buckland, R.; Wild, T.F.; Horvat, B. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. *Virology* **2009**, *387*, 459–465.
 109. Rockx, B.; Bossart, K.N.; Feldmann, F.; Geisbert, J.B.; Hickey, A.C.; Brining, D.; Callison, J.; Safronetz, D.; Marzi, A.; Kercher, L.; Long, D.; Broder, C.C.; Feldmann, H.; Geisbert, T.W. A Novel Model of Lethal Hendra Virus Infection in African Green Monkeys and the Effectiveness of Ribavirin Treatment. *Journal of Virology* **2010**, *84*, 9831–9839. doi:10.1128/JVI.01163-10.
 110. Geisbert, T.W.; Mire, C.E.; Geisbert, J.B.; Chan, Y.P.; Agans, K.N.; Feldmann, F.; Fenton, K.A.; Zhu, Z.; Dimitrov, D.S.; Scott, D.P.; Bossart, K.N.; Feldmann, H.; Broder, C.C. Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. *Science Translational Medicine* **2014**, *6*, 242ra82–242ra82. doi:10.1126/scitranslmed.3008929.
 111. Satterfield, B.A.; Cross, R.W.; Fenton, K.A.; Agans, K.N.; Basler, C.F.; Geisbert, T.W.; Mire, C.E. The Immunomodulating V and W Proteins of Nipah Virus Determine Disease Course. *Nature Communications* **2015**, *6*, 7483. doi:10.1038/ncomms8483.
 112. Satterfield, B.A.; Cross, R.W.; Fenton, K.A.; Borisevich, V.; Agans, K.N.; Deer, D.J.; Graber, J.; Basler, C.F.; Geisbert, T.W.; Mire, C.E. Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. *Journal of Virology* **2016**, *90*, 6326–6343. doi:10.1128/JVI.00215-16.
 113. Guillaume-Vasselin, V.; Lemaitre, L.; Dhondt, K.P.; Tedeschi, L.; Poulard, A.; Charreyre, C.; Horvat, B. Protection from Hendra virus infection with Canarypox recombinant vaccine. *npj Vaccines* **2016**, *1*, 1–8.
 114. Wong, K.T.; Shieh, W.J.; Kumar, S.; Norain, K.; Abdullah, W.; Guarner, J.; Goldsmith, C.S.; Chua, K.B.; Lam, S.K.; Tan, C.T.; others. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. *The American journal of pathology* **2002**, *161*, 2153–2167.
 115. Pasquale, E.B. Eph-ephrin bidirectional signaling in physiology and disease. *Cell* **2008**, *133*, 38–52.

116. Genzer, S.C.; Welch, S.R.; Scholte, F.E.M.; Harmon, J.R.; Coleman-McCray, J.D.; Lo, M.K.; Montgomery, J.M.; Nichol, S.T.; Spiropoulou, C.F.; Spengler, J.R. Alterations in Blood Chemistry Levels Associated With Nipah Virus Disease in the Syrian Hamster Model. *The Journal of Infectious Diseases* **2019**. doi:10.1093/infdis/jiz552.
117. Kasloff, S.; Leung, A.; Pickering, B.; Smith, G.; Moffat, E.; Collignon, B.; Embury-Hyatt, C.; Kobasa, D.; Weingartl, H. Pathogenicity of Nipah henipavirus Bangladesh in a swine host. *Scientific reports* **2019**, *9*, 1–11.
118. Weingartl, H.; Czub, S.; Copps, J.; Berhane, Y.; Middleton, D.; Marszal, P.; Gren, J.; Smith, G.; Ganske, S.; Manning, L.; Czub, M. Invasion of the Central Nervous System in a Porcine Host by Nipah Virus. *Journal of Virology* **2005**, *79*, 7528–7534. doi:10.1128/JVI.79.12.7528-7534.2005.
119. Middleton, D.; Westbury, H.; Morrissy, C.; Van der Heide, B.; Russell, G.; Braun, M.; Hyatt, A. Experimental Nipah virus infection in pigs and cats. *Journal of comparative pathology* **2002**, *126*, 124–136.
120. Weingartl, H.M.; Berhane, Y.; Caswell, J.L.; Loosmore, S.; Audonnet, J.C.; Roth, J.A.; Czub, M. Recombinant Nipah Virus Vaccines Protect Pigs against Challenge. *Journal of Virology* **2006**, *80*, 7929–7938. doi:10.1128/JVI.00263-06.
121. Berhane, Y.; Weingartl, H.; Lopez, J.; Neufeld, J.; Czub, S.; Embury-Hyatt, C.; Goolia, M.; Copps, J.; Czub, M. Bacterial infections in pigs experimentally infected with Nipah virus. *Transboundary and emerging diseases* **2008**, *55*, 165–174.
122. Mungall, B.A.; Middleton, D.; Crameri, G.; Halpin, K.; Bingham, J.; Eaton, B.T.; Broder, C.C. Vertical Transmission and Fetal Replication of Nipah Virus in an Experimentally Infected Cat. *The Journal of Infectious Diseases* **2007**, *196*, 812–816. doi:10.1086/520818.
123. Pallister, J.; Middleton, D.; Wang, L.F.; Klein, R.; Haining, J.; Robinson, R.; Yamada, M.; White, J.; Payne, J.; Feng, Y.R.; others. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. *Vaccine* **2011**, *29*, 5623–5630.
124. Clayton, B.A.; Middleton, D.; Bergfeld, J.; Haining, J.; Arkininstall, R.; Wang, L.; Marsh, G.A. Transmission routes for Nipah virus from Malaysia and Bangladesh. *Emerging infectious diseases* **2012**, *18*, 1983.
125. Clayton, B.A.; Middleton, D.; Arkininstall, R.; Frazer, L.; Wang, L.F.; Marsh, G.A. The nature of exposure drives transmission of Nipah viruses from Malaysia and Bangladesh in ferrets. *PLoS neglected tropical diseases* **2016**, *10*, e0004775.
126. Williamson, M.; Hooper, P.; Selleck, P.; Westbury, H.; Slocombe, R. Experimental hendra virus infection in pregnant guinea-pigs and fruit Bats (*Pteropus poliocephalus*). *Journal of comparative pathology* **2000**, *122*, 201–207.
127. Middleton, D.; Morrissy, C.; van der Heide, B.; Russell, G.; Braun, M.; Westbury, H.; Halpin, K.; Daniels, P. Experimental Nipah Virus Infection in Pteropid Bats (*Pteropus Poliocephalus*). *Journal of Comparative Pathology* **2007**, *136*, 266–272. doi:10.1016/j.jcpa.2007.03.002.
128. Freiberg, A.N.; Worthy, M.N.; Lee, B.; Holbrook, M.R. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. *The Journal of general virology* **2010**, *91*, 765.
129. Van Doremalen, N.; Lambe, T.; Sebastian, S.; Bushmaker, T.; Fischer, R.; Feldmann, F.; Haddock, E.; Letko, M.; Avanzato, V.A.; Rissanen, I.; others. A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. *PLoS neglected tropical diseases* **2019**, *13*, e0007462.
130. Wong, K.T.; Grosjean, I.; Brisson, C.; Blanquier, B.; Fevre-Montange, M.; Bernard, A.; Loth, P.; Georges-Courbot, M.C.; Chevallier, M.; Akaoka, H.; others. A golden hamster model for human acute Nipah virus infection. *The American journal of pathology* **2003**, *163*, 2127–2137.
131. Welch, S.R.; Scholte, F.E.; Harmon, J.R.; Coleman-McCray, J.D.; Lo, M.K.; Montgomery, J.M.; Nichol, S.T.; Spiropoulou, C.F.; Spengler, J.R. In situ imaging of fluorescent Nipah virus respiratory and neurological tissue tropism in the Syrian hamster model. *The Journal of infectious diseases* **2020**, *221*, S448–S453.
132. DeBuysscher, B.L.; Scott, D.; Marzi, A.; Prescott, J.; Feldmann, H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. *Vaccine* **2014**, *32*, 2637–2644.
133. De Wit, E.; Bushmaker, T.; Scott, D.; Feldmann, H.; Munster, V.J. Nipah virus transmission in a hamster model. *PLoS Negl Trop Dis* **2011**, *5*, e1432.

134. Dawes, B.E.; Kalveram, B.; Ikegami, T.; Juelich, T.; Smith, J.K.; Zhang, L.; Park, A.; Lee, B.; Komeno, T.; Furuta, Y.; others. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. *Scientific reports* **2018**, *8*, 1–11.
135. Lo, M.K.; Bird, B.H.; Chattopadhyay, A.; Drew, C.P.; Martin, B.E.; Coleman, J.D.; Rose, J.K.; Nichol, S.T.; Spiropoulou, C.F. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. *Antiviral research* **2014**, *101*, 26–29.
136. Dups, J.; Middleton, D.; Yamada, M.; Monaghan, P.; Long, F.; Robinson, R.; Marsh, G.A.; Wang, L.F. A New Model for Hendra Virus Encephalitis in the Mouse. *PLoS ONE* **2012**, *7*, e40308. doi:10.1371/journal.pone.0040308.
137. Dups, J.; Middleton, D.; Long, F.; Arkinstall, R.; Marsh, G.A.; Wang, L.F. Subclinical infection without encephalitis in mice following intranasal exposure to Nipah virus-Malaysia and Nipah virus-Bangladesh. *Virology journal* **2014**, *11*, 102.
138. Murray, K.; Selleck, P.; Hooper, P.; Hyatt, A.; Gould, A.; Gleeson, L.; Westbury, H.; Hiley, L.; Selvey, L.; Rodwell, B.; others. A morbillivirus that caused fatal disease in horses and humans. *Science* **1995**, *268*, 94–97.
139. Hanna, J.N.; McBride, W.J.; Brookes, D.L.; Shield, J.; Taylor, C.T.; Smith, I.L.; Craig, S.B.; Smith, G.A. Hendra virus infection in a veterinarian. *The Medical Journal of Australia* **2006**, *185*, 562.
140. Tanimura, N.; Imada, T.; Kashiwazaki, Y.; Shahirudin, S.; Sharifah, S.; Aziz, A. Monoclonal antibody-based immunohistochemical diagnosis of Malaysian Nipah virus infection in pigs. *Journal of comparative pathology* **2004**, *131*, 199–206.
141. Selvey, L.A.; Wells, R.M.; McCormack, J.G.; Ansford, A.J.; Murray, K.; Rogers, R.J.; Lavercombe, P.S.; Selleck, P.; Sheridan, J.W. Infection of humans and horses by a newly described morbillivirus. *Medical Journal of Australia* **1995**, *162*, 642–644.
142. Wong, K.; Robertson, T.; Ong, B.; Chong, J.; Yaiw, K.; Wang, L.; Ansford, A.; Tannenbergh, A. Human Hendra virus infection causes acute and relapsing encephalitis. *Neuropathology and applied neurobiology* **2009**, *35*, 296–305.
143. Hooijmans, C.; Ritskes-Hoitinga, M. Progress in using systematic reviews of animal studies to improve translational research. *PLoS Med* **2013**, *10*, e1001482.
144. Bonapersona, V.; Hooijmans, H.; Sarabdjitsingh, R.; Joëls, M. Increasing the statistical power of animal experiments with historical control data. *Nature Neuroscience* **2021**, *24*, 470–477.
145. Chretien, J.P.; Rivers, C.M.; Johansson, M.A. Make data sharing routine to prepare for public health emergencies. *PLoS medicine* **2016**, *13*, e1002109.
146. Roche, D.G.; Kruuk, L.E.; Lanfear, R.; Binning, S.A. Public data archiving in ecology and evolution: how well are we doing? *PLoS Biol* **2015**, *13*, e1002295.
147. Colvin, M.E.; Peterson, J.T.; Kent, M.L.; Schreck, C.B. Occupancy modeling for improved accuracy and understanding of pathogen prevalence and dynamics. *PloS one* **2015**, *10*, e0116605.
148. MacKenzie, D.I.; Royle, J.A. Designing occupancy studies: general advice and allocating survey effort. *Journal of Applied Ecology* **2005**, *42*, 1105–1114.
149. Pacifici, K.; Dorazio, R.M.; Conroy, M.J. A two-phase sampling design for increasing detections of rare species in occupancy surveys. *Methods in Ecology and Evolution* **2012**, *3*, 721–730.
150. DiRenzo, G.V.; Campbell Grant, E.H.; Longo, A.V.; Che-Castaldo, C.; Zamudio, K.R.; Lips, K.R. Imperfect pathogen detection from non-invasive skin swabs biases disease inference. *Methods in Ecology and Evolution* **2018**, *9*, 380–389.
151. Chua, K.; Bellini, W.; Rota, P.; Harcourt, B.; Tamin, A.; Lam, S.; Ksiazek, T.; Rollin, P.; Zaki, S.; Shieh, W.J.; others. Nipah virus: a recently emergent deadly paramyxovirus. *Science* **2000**, *288*, 1432–1435.
152. Young, D.; Andrejeva, L.; Livingstone, A.; Goodbourn, S.; Lamb, R.; Collins, P.; Elliott, R.; Randall, R. Virus replication in engineered human cells that do not respond to interferons. *Journal of virology* **2003**, *77*, 2174–2181.
153. Cramer, G.; Todd, S.; Grimley, S.; McEachern, J.A.; Marsh, G.A.; Smith, C.; Tachedjian, M.; De Jong, C.; Virtue, E.R.; Yu, M.; others. Establishment, immortalisation and characterisation of pteropid bat cell lines. *PloS one* **2009**, *4*, e8266.
154. Duncan, R. Fusogenic reoviruses and their fusion-associated small transmembrane (FAST) proteins. *Annual review of virology* **2019**, *6*, 341–363.

155. Bracq, L.; Xie, M.; Lambelé, M.; Vu, L.T.; Matz, J.; Schmitt, A.; Delon, J.; Zhou, P.; Randriamampita, C.; Bouchet, J.; others. T cell-macrophage fusion triggers multinucleated giant cell formation for HIV-1 spreading. *Journal of virology* **2017**, *91*.
156. Dederá, D.; Ratner, L. Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants. *Journal of virology* **1991**, *65*, 6129–6136.
157. Nardacci, R.; Perfettini, J.; Grieco, L.; Thieffry, D.; Kroemer, G.; Piacentini, M. Syncytial apoptosis signaling network induced by the HIV-1 envelope glycoprotein complex: an overview. *Cell death & disease* **2015**, *6*, e1846–e1846.
158. Rockx, B.; Brining, D.; Kramer, J.; Callison, J.; Ebihara, H.; Mansfield, K.; Feldmann, H. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. *Journal of virology* **2011**, *85*, 7658–7671.
159. Erbar, S.; Maisner, A. Nipah virus infection and glycoprotein targeting in endothelial cells. *Virology Journal* **2010**, *7*, 305.
160. Zamora, J.L.R.; Aguilar, H.C. Flow virometry as a tool to study viruses. *Methods* **2018**, *134*, 87–97.
161. Mathieu, C.; Dhondt, K.P.; Châlons, M.; Mély, S.; Raoul, H.; Negre, D.; Cosset, F.L.; Gerlier, D.; Vivès, R.R.; Horvat, B. Heparan sulfate-dependent enhancement of henipavirus infection. *MBio* **2015**, *6*.
162. Burton, C.; Bartee, E. Syncytia formation in oncolytic virotherapy. *Molecular Therapy-Oncolytics* **2019**, *15*, 131–139.
163. Fujii, M.; Sato, T. Somatic cell-derived organoids as prototypes of human epithelial tissues and diseases. *Nature Materials* **2020**, pp. 1–14.
164. Tang, H.; Abouleila, Y.; Si, L.; Ortega-Prieto, A.M.; Mummery, C.L.; Ingber, D.E.; Mashaghi, A. Human organs-on-chips for virology. *Trends in Microbiology* **2020**.
165. Sachs, N.; Papaspyropoulos, A.; Zomer-van Ommen, D.D.; Heo, I.; Böttinger, L.; Klay, D.; Weeber, F.; Huelsz-Prince, G.; Iakobachvili, N.; Amatngalim, G.D.; others. Long-term expanding human airway organoids for disease modeling. *The EMBO journal* **2019**, *38*, e100300.
166. Russell, C.A.; Kasson, P.M.; Donis, R.O.; Riley, S.; Dunbar, J.; Rambaut, A.; Asher, J.; Burke, S.; Davis, C.T.; Garten, R.J.; others. Science Forum: improving pandemic influenza risk assessment. *Elife* **2014**, *3*, e03883.